Tracking Baker Brothers Portfolio – Q1 2020 Update

• Baker Brothers’ 13F portfolio value decreased from $18.81B to $16.24B this quarter. 
• Madrigal Pharma stake was increased while decreasing Exact Sciences during the quarter. 
• The top-three positions are Seattle Genetics, Incyte Corporation, and Acadia Pharma and they add up to almost ~61% of the portfolio.

This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 05/15/2020.

This quarter, Baker Brothers’ 13F portfolio value decreased ~14% from $18.81B to ~$16.24B. The top three holdings are at ~61% while the top five holdings are at ~75% of the 13F assets: Seattle Genetics (SGEN), Incyte Corporation (INCY), Acadia Pharma (ACAD), BeiGene (BGNE), and Alexion Pharmaceuticals (ALXN).

The spreadsheet below highlights changes to Baker Brothers’ 13F holdings in Q1 2020. For a look at how the portfolio has progressed, please see our previous update:

To learn more about how to profit from a strategy of following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little Guy .